Overview

SCMC Trial on KHE With KMP (V.2020)

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
0
Participant gender:
All
Summary
a phase I trial focusing on safety and efficacy of prednison shock plus sirolimus maintenance in treating Kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt phenomenon (KMP)
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shanghai Children's Medical Center
Treatments:
Sirolimus
Criteria
Inclusion Criteria:

- Kaposiform Hemangioendotheliomas with Kasabach-Merritt Phenomenon

- 0 - 12 years of age at the time of study entry

- Male or female

- Consent of parents (or the person having parental authority in families)

- Signed and dated written informed consent

Exclusion Criteria:

- with hematological diseases

- with other solid tumors

- with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and
kidney

- dysfunction, and cardiopulmonary insufficiency

- with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the
treatment